Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 0.76 |
| ▸ | CDK9 | P50750 | 14/20 | 0.76 |
| ▸ | DYRK2 | Q92630 | 16/20 | 0.72 |
| ▸ | CLK1 | P49759 | 4/20 | 0.72 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.72 |
| ▸ | CLK2 | P49760 | 2/20 | 0.72 |
| ▸ | CLK3 | P49761 | 2/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.72 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.72 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.72 |
| ▸ | DYRK4 | Q9NR20 | 2/20 | 0.72 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.72 |
| ▸ | GSK3B | P49841 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20508634 | 0.89 | DYRK1A (0.85) | DYRK1ACDK9DYRK2CLK1CSNK1E | |
| SCHEMBL20508622 | 0.87 | DYRK1A (1.00) | DYRK1ACDK9DYRK2CLK1CSNK1E | |
| SCHEMBL20508601 | 0.85 | DYRK1A (0.76) | DYRK1ACDK9DYRK2CLK1CSNK1E | |
| SCHEMBL20508570 | 0.85 | DYRK1A (0.93) | DYRK1ACDK9DYRK2CLK1CSNK1E | |
| SCHEMBL20508715 | 0.85 | DYRK1A (0.79) | DYRK1ACDK9DYRK2CLK1CSNK1E | |
| SCHEMBL20508420 | 0.85 | DYRK1A (0.75) | DYRK1ACDK9DYRK2CLK1CSNK1E | |
| SCHEMBL20508469 | 0.85 | DYRK1A (0.79) | DYRK1ACDK9DYRK2CLK1CSNK1E | |
| SCHEMBL20508603 | 0.84 | DYRK1A (0.91) | DYRK1ACDK9DYRK2CLK1CSNK1E | |
| SCHEMBL20508495 | 0.84 | DYRK1A (1.00) | DYRK1ACDK9DYRK2CLK1CSNK1E | |
| SCHEMBL20508502 | 0.84 | DYRK1A (0.66) | DYRK1ACDK9DYRK2CLK1CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-09-27 | — | — | US | claimed |
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273528-A1 | IMIDAZO[4,5-b]PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDH2, CYP4B1, RB1 | DYRK1A 2020/4885CDK9 331/4885DYRK2 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.